A5040295868- Diabetes, Cardiovascular Risks, and Lipoproteins
- Lipid metabolism and disorders
- X-ray Diffraction in Crystallography
- Crystallization and Solubility Studies
- Cancer, Lipids, and Metabolism
- Diabetes and associated disorders
- Lipoproteins and Cardiovascular Health
- Caveolin-1 and cellular processes
- Cholesterol and Lipid Metabolism
- RNA Interference and Gene Delivery
- Pancreatitis Pathology and Treatment
- Lipid Membrane Structure and Behavior
- Antimicrobial Peptides and Activities
- Molecular Sensors and Ion Detection
- Signaling Pathways in Disease
- thermodynamics and calorimetric analyses
- Pancreatic and Hepatic Oncology Research
- Blood properties and coagulation
- Advanced Proteomics Techniques and Applications
- Metabolomics and Mass Spectrometry Studies
- Cardiac Imaging and Diagnostics
- Lipid metabolism and biosynthesis
- Monoclonal and Polyclonal Antibodies Research
- Metabolism, Diabetes, and Cancer
- RNA modifications and cancer
Tallinn University of Technology
2015-2024
National Heart Lung and Blood Institute
2021-2024
National Institutes of Health
2021-2024
Chiral (<italic>all-R</italic>)-cyclohexanohemicucurbit[8]uril binds anions in a 1 : ratio pure methanol like molecular Pac-Man™ with remarkable selectivity based on the size, shape and charge distribution of anion.
LPL hydrolyzes triglycerides in plasma lipoproteins. Due to the complex regulation mechanism, it has been difficult mimic physiological conditions under which acts vitro. We demonstrate that isothermal titration calorimetry (ITC), using human as substrate, overcomes several limitations of previously used techniques. The high sensitivity ITC allows continuous recording heat released during hydrolysis. Both initial rates and kinetics for complete hydrolysis lipids can be studied. rate was...
Background. Although traditional lipid parameters and coronary imaging techniques are valuable for cardiovascular disease (CVD) risk prediction, better diagnostic tests still needed.
Defects in lipolysis can lead to hypertriglyceridemia, which trigger acute pancreatitis and is also associated with cardiovascular disease. Decreasing plasma triglycerides (TGs) by activating lipoprotein lipase (LPL) ApoC2 mimetic peptides a new treatment strategy for hypertriglyceridemia. We recently described dual mimetic/ApoC3 antagonist peptide called D6PV that effectively lowered TG several mouse models but has limitations terms of drug development. The aim this study was create the...
Amphipathic arginine-rich peptide, A2-17, exhibits moderate perturbation of lipid membranes and the highest cell penetration among its structural isomers. We investigated direct cell-membrane mechanism A2-17 peptide while focusing on flexibility. designed conformationally constrained versions stapled (StpA2-17) stitched (StchA2-17), whose α-helical conformations were stabilized by chemical crosslinking. Circular dichroism confirmed that StpA2-17 StchA2-17 had higher α-helix content than in...
<title>Abstract</title> GPIHBP1 is a membrane protein of endothelial cells that transports lipoprotein lipase (LPL), the key enzyme in plasma triglyceride metabolism, from interstitial space to its site action on capillary lumen. An intrinsically disordered highly negatively charged N-terminal domain contributes interaction with LPL. In this work, we investigated whether plethora heparin-binding proteins positively regions found human affect interaction. We also wanted know role purely...
GPIHBP1 is a membrane protein of endothelial cells that transports lipoprotein lipase (LPL), the key enzyme in plasma triglyceride metabolism, from interstitial space to its site action on capillary lumen. An intrinsically disordered highly negatively charged N-terminal domain contributes interaction with LPL. In this work, we investigated whether plethora heparin-binding proteins positively regions found human affect interaction. We also wanted know role purely non-specific and supportive...
The metabolism of triglyceride-rich lipoproteins plays an important role in cardiovascular diseases and dyslipidemias. Lowering plasma triglycerides (TGs) by activating lipoprotein lipase (LPL), the main enzyme that hydrolyses TGs, with ApoC-II mimetic peptides is a potential strategy for treatment deficiency, potentially other forms hypertriglyceridemia.We previously described dual mimetic/ApoC-III antagonist peptide called D6-PV. It’s bihelical, 41 amino acid long first helix designed to...
ApoE facilitates the clearance of apoB-containing lipoproteins by binding to heparan sulfate proteoglycans (HSPG), low density lipoprotein receptor (LDLR) and LDLR-related protein 1 (LRP1). has a lipid domain, which are both needed for its biological function. Several apoE-based peptides have been developed that lower plasma levels in animal models early-stage clinical trials. However, these long (28-61 residues), costly synthesize potentially immunogenic as they often contain many amino...